Eli Lilly Stock News

Eli Lilly shares have climbed in the triple digits over the past year, and earnings have soared too. The company sells two of the world's most sought-after products right now: weight-loss drugs.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity candi

The pharmaceutical and e-commerce industries have proven to be resilient places to invest. Eli Lilly is riding a wave of sales from new blockbuster drugs on top of its flagship products.

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as El

International Companies Drive Diabesity Innovation

Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.

Eli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024. Its diabetes treatments look particularly encouraging, with Mounjaro's 11

Eva Ados, ERShares chief investment strategist, joins 'Power Lunch' to discuss plays for three stocks, including Meta Platforms, Disney, and Eli Lilly.

The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i

Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.

Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have

The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina

In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.